(Bold for FDA approved)
How Medistat works• Binds to benzodiazepine receptors at the GABA-A ligand-gated chloride channel complex
• Enhances the inhibitory effects of GABA
• Boosts chloride conductance through GABA-regulated channels
• Inhibitory actions in sleep centers may provide sedative hypnotic effects
• Intravenous injection: onset 3–5 minutes
• Intramuscular injection: onset 15 minutes, peak 30–60 minutes
Notable Side Effects• Oversedation, impaired recall, agitation, involuntary movements, headache
• Nausea, vomiting
• Hiccups, fluctuation in vital signs, irritation/ pain at site of injection
• Hypotension
Life Threatening Side Effects• Respiratory depression, apnea, respiratory arrest
• Cardiac arrest

unusual

common
• Wait
• Switch to another agent
• Administer flumazenil if side effects are severe or life-threatening
• Intravenous (adults): 1–2.5 mg
• Liquid (age 16 and under): 0.25–1.0 mg/kg
Dosage Forms• Syrup 2 mg/mL
• Nasal 5 mg/spray
• Intravenous 1 mg/mL, 5 mg/mL
• Intramuscular solution 50 mg/10 mL (5 mg/mL)
• Not generally intended for long-term use
• Some patients may develop dependence and/or tolerance; risk may be greater with higher doses
• History of drug addiction may increase risk of dependence
Renal Impairment• May have longer elimination half-life, prolonging time to recovery
Hepatic Impairment• Longer elimination half-life; clearance is reduced
Cardiac Impairment• Longer elimination half-life; clearance is reduced
Elderly• Longer elimination half-life; clearance is reduced
• Intravenous: 1–3.5 mg; maximum 1.5 mg within 2 minutes
Children and Adolescents• In most pediatric populations, pharmacokinetic properties are similar to those in adults
• Seriously ill neonates have reduced clearance and longer elimination half-life
• Hypotension has occurred in neonates given midazolam and fentanyl
• Intravenous dose: dependent on age, weight, route, procedure
Pregnancy• Effective June 30, 2015, the FDA requires changes to the content and format of pregnancy and lactation information in prescription drug labels, including the elimination of the pregnancy letter categories; the Pregnancy and Lactation Labeling Rule (PLLR or final rule) applies only to prescription drugs and will be phased in gradually for drugs approved on or after June 30, 2001
• Controlled studies have not been conducted in pregnant women
• Midazolam crosses the placenta
• Neonatal flaccidity has been reported in infants whose mother took a benzodiazepine during pregnancy
Breast Feeding• Some drug is found in mother’s breast milk
• Effects on infant have been observed and include feeding difficulties, sedation, and weight loss
• Midazolam can be used to relieve postoperative pain after cesarean section
Based on data Published online by Cambridge University Press
Compiled by Dr. Jash Ajmera